Cargando…

Intravenous Phosphate Loading Increases Fibroblast Growth Factor 23 in Uremic Rats

Oral phosphate loading and calcitriol stimulate Fibroblast growth factor 23 (FGF23) secretion, but the mechanisms underlying the stimulation of FGF23 remain to be studied. We compared the effect of intravenous phosphate loading with that of oral loading on FGF23 levels in normal and 5/6 nephrectomiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai-Nunota, Noriko, Mizobuchi, Masahide, Ogata, Hiroaki, Yamazaki-Nakazawa, Ai, Kumata, Chiaki, Kondo, Fumiko, Hosaka, Nozomu, Koiwa, Fumihiko, Kinugasa, Eriko, Shibata, Takanori, Akizawa, Tadao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953214/ https://www.ncbi.nlm.nih.gov/pubmed/24625659 http://dx.doi.org/10.1371/journal.pone.0091096

Ejemplares similares

Clinical significance of parathyroid intervention on CKD-MBD management
por: Ogata, Hiroaki, et al.
Publicado: (2008)

The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study
por: Ogata, Hiroaki, et al.
Publicado: (2017)

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment
por: Koiwa, Fumihiko, et al.
Publicado: (2018)

Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study
por: Hasegawa, Takeshi, et al.
Publicado: (2018)

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open‐label, multicentre, 12‐week phase III study
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants
por: Koiwa, Fumihiko, et al.
Publicado: (2022)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023)

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
por: Kazama, Junichiro James, et al.
Publicado: (2022)

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients
por: Onoda, Noritaka, et al.
Publicado: (2008)

Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention
por: Kakuta, Takatoshi, et al.
Publicado: (2008)

Effect of erythropoietin-stimulating agent on uremic inflammation
por: Tanaka, Yuri, et al.
Publicado: (2012)

Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study
por: Kinugasa, Eriko, et al.
Publicado: (2021)

Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study
por: Inaguma, Daijo, et al.
Publicado: (2023)

A Novel Uremic Score Reflecting Accumulation of Specific Uremic Toxins More Precisely Predicts One-Year Mortality after Hemodialysis Commencement: A Retrospective Cohort Study
por: Arai, Yohei, et al.
Publicado: (2020)

Hemolytic Uremic Syndrome-associated Encephalopathy Successfully Treated with Corticosteroids
por: Hosaka, Takashi, et al.
Publicado: (2017)

Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies
por: Akizawa, Tadao, et al.
Publicado: (2020)

Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial
por: Ogata, Hiroaki, et al.
Publicado: (2020)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

MPO-ANCA crescentic glomerulonephritis complicated by membranous nephropathy: MPO demonstrated in epimembranous deposits
por: Matsumoto, Kei, et al.
Publicado: (2009)

Design and baseline characteristics of the LANDMARK study
por: Ogata, Hiroaki, et al.
Publicado: (2016)

Possible prevention of uremic nausea by vitamin D receptor activators in non-dialysis patients with stage 5 chronic kidney disease
por: Ikeda, Masato, et al.
Publicado: (2016)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia
por: Fukagawa, Masafumi, et al.
Publicado: (2008)

High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients
por: Honda, Hirokazu, et al.
Publicado: (2017)

Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
por: Koiwa, Fumihiko, et al.
Publicado: (2016)

Cellular changes following direct vitamin D injection into the uraemia-induced hyperplastic parathyroid gland
por: Shiizaki, Kazuhiro, et al.
Publicado: (2008)

Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis
por: Akizawa, Tadao, et al.
Publicado: (2021)

Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study
por: Akizawa, Tadao, et al.
Publicado: (2018)

Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS)
por: Kido, Ryo, et al.
Publicado: (2019)

Uremic stomatitis
por: Sudarshan, Ramachandran, et al.
Publicado: (2012)

Uremic osteoporosis
por: Kazama, Junichiro J, et al.
Publicado: (2013)

Uremic frost
por: Raina, Sujeet, et al.
Publicado: (2014)

Uremic frost
por: Mathur, Mohit, et al.
Publicado: (2014)

Uremic stomatitis()
por: Souza, Paulo Ricardo Martins, et al.
Publicado: (2022)

Uremic Sarcopenia
por: Mohanasundaram, Subashri, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1frijp1v08o116gij7jkio68a1